申请人:Pfizer Inc.
公开号:US04829062A1
公开(公告)日:1989-05-09
A series of novel oxyalkyl ether derivatives of various enolic oxicam compounds have been prepared, including certain novel enol oxyalkyl ethers of 4-hydroxy-2-methyl-N-(2-pyridinyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide (piroxicam). These particular compounds are useful in theraphy as prodrug forms of the known anti-inflammatory and analgesic oxicams. Typical and preferred member compounds include 4-[3-(hydroxy)-n-propyloxy]-2-methyl-N-(2-pyridinyl)-2H-1,2-benzothiazine- 3-carboxamide 1,1-dioxide, 4-[5-(hydroxy)-n-pentyloxy]-2-methyl-N-(2-pyridinyl)-2H-1,2-benzothiazine- 3-carboxamide 1,1-dioxide, 4-[3-(methoxycarbonyloxy)-n-propyloxy]-2-methyl-N-(2-pyridinyl)-2H-1,2-ben zothiazine-3-carboxamide 1,1-dioxide, 4-[3-(ethoxycarbonyloxy)-n-propyloxy]-2-methyl-N-(2-pyridinyl)-2H-1,2-benz othiazine-3-carboxamide 1,1-dioxide, 4-[4-(ethoxycarbonyloxy)-n-butyloxy]-2-methyl-N-(2-pyridinyl-2H-1,2-benzot hiazine-3-carboxamide 1,1-dioxide and 2-methyl-4-[3-(n-octyloxycarbonyloxy)-n-propyloxy]-N-(-2-pyridinyl)-2H-1,2 -benzothiazine-3-carboxamide 1,1-dioxide. Methods for preparing these compounds from known starting material are provided.
已合成一系列新颖的各种烯醇氧烷醚衍生物,包括某些新颖的4-羟基-2-甲基-N-(2-吡啶基)-2H-1,2-苯并噻嗪-3-羧酰胺-1,1-二氧化物(吡罗昔康)的烯醇氧烷醚。这些特定化合物在治疗中很有用,作为已知抗炎和镇痛噻嗪的前药形式。典型和首选的成员化合物包括4-[3-(羟基)-正丙氧基]-2-甲基-N-(2-吡啶基)-2H-1,2-苯并噻嗪-3-羧酰胺-1,1-二氧化物,4-[5-(羟基)-正戊氧基]-2-甲基-N-(2-吡啶基)-2H-1,2-苯并噻嗪-3-羧酰胺-1,1-二氧化物,4-[3-(甲氧羰氧基)-正丙氧基]-2-甲基-N-(2-吡啶基)-2H-1,2-苯并噻嗪-3-羧酰胺-1,1-二氧化物,4-[3-(乙氧羰氧基)-正丙氧基]-2-甲基-N-(2-吡啶基)-2H-1,2-苯并噻嗪-3-羧酰胺-1,1-二氧化物,4-[4-(乙氧羰氧基)-正丁氧基]-2-甲基-N-(2-吡啶基)-2H-1,2-苯并噻嗪-3-羧酰胺-1,1-二氧化物和2-甲基-4-[3-(正辛氧羰氧基)-正丙氧基]-N-(-2-吡啶基)-2H-1,2-苯并噻嗪-3-羧酰胺-1,1-二氧化物。提供了从已知起始物质制备这些化合物的方法。